Stocks and Investing Stocks and Investing
Fri, March 20, 2020

Gena Wang Initiated (VRTX) at Buy on, Mar 20th, 2020


Published on 2024-10-27 00:29:49 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy on, Mar 20th, 2020.

Gena has made no other calls on VRTX in the last 4 months.



There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Brian Skorney of "Baird" Downgraded from Buy to Hold and Increased Target to $230 on, Friday, January 31st, 2020


These are the ratings of the 9 analyists that currently disagree with Gena


  • Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $275 on, Wednesday, March 11th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $260 on, Friday, January 31st, 2020
  • Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $286 on, Friday, January 31st, 2020
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $251 on, Friday, January 31st, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $275 on, Friday, January 31st, 2020
  • Ying Huang of "B of A Securities" Maintained at Strong Buy with Increased Target to $295 on, Friday, January 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $258 on, Friday, January 31st, 2020
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $265 on, Wednesday, January 8th, 2020
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $284 on, Monday, January 6th, 2020
Contributing Sources